glp 1 without bmi requirement GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or type 2 diabetes mellitus: a systematic review and meta-analysis Medicare to Cover GLP-1 Weight

doi: 10.1016/j.metabol.2021.154871, PMID: [DOI] [PubMed] [Google Scholar] 50

Early data on oral versus injectable tirzepatide is still limited, but it is worth monitoring as more results become available

Dose reduction Reducing the semaglutide dose is often the first strategy considered, and for good reason

Compounded semaglutide products are not required to go through the same type of testing, so they are not evaluated for safety, effectiveness, or quality, in the same ways that FDA-approved drugs like Ozempic are

The higher-dose semaglutide formulation for obesity (Wegovy, 2.4 mg weekly) can produce 10-15% weight loss, while diabetes doses typically yield more modest reductions

For obesity and weight loss patients, the delayed digestion and feeling of fullness promotes weight loss